image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - US
$ 149.1
-1.73 %
$ 66.8 B
Market Cap
27.21
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ZTS stock under the worst case scenario is HIDDEN Compared to the current market price of 149 USD, Zoetis Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ZTS stock under the base case scenario is HIDDEN Compared to the current market price of 149 USD, Zoetis Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ZTS stock under the best case scenario is HIDDEN Compared to the current market price of 149 USD, Zoetis Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ZTS

image
$195.0$195.0$190.0$190.0$185.0$185.0$180.0$180.0$175.0$175.0$170.0$170.0$165.0$165.0$160.0$160.0$155.0$155.0$150.0$150.0$145.0$145.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
9.26 B REVENUE
8.33%
6.25 B OPERATING INCOME
103.71%
2.5 B NET INCOME
6.48%
2.95 B OPERATING CASH FLOW
25.50%
-315 M INVESTING CASH FLOW
59.46%
-2.66 B FINANCING CASH FLOW
14.44%
2.32 B REVENUE
-2.97%
0 OPERATING INCOME
0.00%
581 M NET INCOME
-16.04%
905 M OPERATING CASH FLOW
-4.84%
126 M INVESTING CASH FLOW
170.79%
-745 M FINANCING CASH FLOW
-18.63%
Balance Sheet Zoetis Inc.
image
Current Assets 5.99 B
Cash & Short-Term Investments 1.98 B
Receivables 1.32 B
Other Current Assets 2.68 B
Non-Current Assets 8.25 B
Long-Term Investments 0
PP&E 3.61 B
Other Non-Current Assets 4.64 B
13.94 %9.24 %18.86 %25.36 %32.60 %Total Assets$14.2b
Current Liabilities 3.41 B
Accounts Payable 433 M
Short-Term Debt 1.35 B
Other Current Liabilities 1.63 B
Non-Current Liabilities 6.06 B
Long-Term Debt 5.39 B
Other Non-Current Liabilities 661 M
4.57 %14.26 %17.21 %56.98 %6.98 %Total Liabilities$9.5b
EFFICIENCY
Earnings Waterfall Zoetis Inc.
image
Revenue 9.26 B
Cost Of Revenue 2.72 B
Gross Profit 6.54 B
Operating Expenses 6.54 B
Operating Income 6.25 B
Other Expenses 3.76 B
Net Income 2.5 B
10b10b9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b009b(3b)7b(7b)6b(4b)2bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
70.62% GROSS MARGIN
70.62%
67.55% OPERATING MARGIN
67.55%
26.86% NET MARGIN
26.86%
52.12% ROE
52.12%
17.46% ROA
17.46%
40.91% ROIC
40.91%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Zoetis Inc.
image
3b3b2b2b2b2b1b1b500m500m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 2.5 B
Depreciation & Amortization 497 M
Capital Expenditures -655 M
Stock-Based Compensation 74 M
Change in Working Capital 79 M
Others 294 M
Free Cash Flow 2.3 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Zoetis Inc.
image
Wall Street analysts predict an average 1-year price target for ZTS of $228 , with forecasts ranging from a low of $200 to a high of $243 .
ZTS Lowest Price Target Wall Street Target
200 USD 34.14%
ZTS Average Price Target Wall Street Target
228 USD 53.14%
ZTS Highest Price Target Wall Street Target
243 USD 62.98%
Price
Max Price Target
Min Price Target
Average Price Target
250250240240230230220220210210200200190190180180170170160160150150140140May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.26% DIVIDEND YIELD
0.5 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.4001.4001.2001.2001.0001.0000.8000.8000.6000.6000.4000.4000.2000.2000.0000.0000.0830.0950.1050.1260.1640.20.250.3250.3750.4320.50.0830.0950.0950.1050.1050.1260.1640.20.250.3250.3750.4320.50.0830.1260.1640.20.250.3250.3750.4320.0830.330.0950.410.1050.470.1260.560.1640.680.20.850.251.040.3251.280.3751.000.4321.190.880.430.502015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Zoetis Inc.
image
Sold
0-3 MONTHS
372 K USD 3
3-6 MONTHS
617 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
140 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years There are many dividend stocks on equity markets, but not all are attractive to income investors. Those that go beyond paying a quarterly payout but also consistently raise their dividends -- all while having robust businesses that can support their dividend programs for a long time -- are the ones income-seekers want. fool.com - 2 weeks ago
My Top 15 High-Growth Dividend Stocks For April 2025 My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% and is potentially 31% undervalued, poised for strong long-term returns. Dollar cost averaging into the top 15 stocks each month shows a 68.54% success rate, with 61 out of 89 stocks leading to positive gains. seekingalpha.com - 2 weeks ago
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy. Shares in animal pharmaceutical company Zoetis (ZTS 0.14%) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations. fool.com - 3 weeks ago
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. businesswire.com - 3 weeks ago
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company. seekingalpha.com - 3 weeks ago
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors Zoetis (ZTS) closed the most recent trading day at $163.03, moving -0.08% from the previous trading session. zacks.com - 4 weeks ago
Why Zoetis (ZTS) Dipped More Than Broader Market Today The latest trading day saw Zoetis (ZTS) settling at $160.06, representing a -1% change from its previous close. zacks.com - 1 month ago
Zoetis: Focusing On The High Margin Segments The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients. seekingalpha.com - 1 month ago
Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript) Zoetis Inc. (NYSE:ZTS ) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. Thanks for joining us at the Barclays Healthcare Conference. seekingalpha.com - 1 month ago
Zoetis (ZTS) Laps the Stock Market: Here's Why Zoetis (ZTS) reachead $170.37 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close. zacks.com - 1 month ago
My Top 15 High-Growth Dividend Stocks For March 2025 The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate. seekingalpha.com - 1 month ago
Zoetis Inc. (ZTS) BofA Securities 2025 Animal Health Summit (Transcript) Zoetis Inc. (NYSE:ZTS ) BofA Securities 2025 Animal Health Summit February 27, 2025 1:20 PM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Operator Ladies and gentlemen, the program is about to begin. At this time, it is my pleasure to turn the program over to your host, Michael Ryskin. seekingalpha.com - 1 month ago
8. Profile Summary

Zoetis Inc. ZTS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 66.8 B
Dividend Yield 0.26%
Description Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Contact 10 Sylvan Way, Parsippany, NJ, 07054 https://www.zoetis.com
IPO Date Feb. 1, 2013
Employees 13800
Officers Ms. Roxanne Lagano Executive Vice President, General Counsel & Corporate Secretary Mr. Wetteny N. Joseph CPA Executive Vice President & Chief Financial Officer Mr. Nick Ashton Executive Vice President and President of Global Manufacturing & Supply Dr. Robert J. Polzer Ph.D. Executive Vice President and President of Research & Development Mr. Steven Frank Vice President of Investor Relations Ms. Julie A. Fuller Executive Vice President, Chief Human Resources Officer & Global Operations Ms. Jeannette Ferran Astorga Executive Vice President of Corporate Affairs & Communications and Chief Sustainability Officer Mr. Keith Sarbaugh Executive Vice President & Chief Digital and Technology Officer Mr. Jamie Brannan Executive Vice President & Chief Commercial Officer Ms. Kristin C. Peck Chief Executive Officer & Director